<DOC>
	<DOC>NCT02175277</DOC>
	<brief_summary>This is a phase 3b, multi-centre, open-label, single-arm companion study to the MDS 20090160 study for the treatment of anaemic subjects with MDS. Subjects that complete the active-treatment period of the darbepoetin alfa MDS 20090160 study and meet the eligibility criteria may be enrolled into this study to continue treatment of darbepoetin alfa for up to 73 weeks or until progression to acute myelogenous leukemia (AML), whichever occurs first.</brief_summary>
	<brief_title>Darbepoetin Alfa MDS Companion Protocol</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Subject or subject's legally acceptable representative has provided informed consent prior to any studyspecific activities/ procedures being initiated; Subject must continue long term follow up within parent study (20090160); Subject must have an ongoing clinically relevant erythroid response as assessed by the Investigator using current response criteria (ie, International Working Group (IWG) response criteria); Transfusion dependence defined as receiving a total of â‰¥ 4 units of red blood cell (RBC) transfusion in the previous 8week period prior to enrolment; Known diagnosis of acute myelogenous leukemia (AML) or marrow collagen fibrosis; Known refractory anaemia with excess blast2 (RAEB2); Known diagnosis of intermediate2 or high risk MDS per International Prognostic Scoring System (IPSS); Subjects received thrombopoiesisstimulating factors (eg, eltrombopag, romiplostim) in the MDS 20090160 study or planning to receive such agents during the study; Other protocol defined inclusion and exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Myelodysplastic Syndrome (MDS)</keyword>
	<keyword>Darbepoetin alfa</keyword>
	<keyword>low risk MDS</keyword>
	<keyword>intermediate-1 risk MDS</keyword>
	<keyword>International Prognostic Scoring System (IPSS)</keyword>
</DOC>